Collegium Pharmaceutical (NASDAQ:COLL) Earns Overweight Rating from Analysts at Barclays

Barclays initiated coverage on shares of Collegium Pharmaceutical (NASDAQ:COLL) in a research report sent to investors on Monday, Marketbeat.com reports. The brokerage issued an overweight rating and a $58.00 price objective on the specialty pharmaceutical company’s stock.

A number of other equities analysts have also recently issued reports on the company. Needham & Company LLC restated a “buy” rating and set a $46.00 price target on shares of Collegium Pharmaceutical in a report on Tuesday, October 28th. Truist Financial increased their target price on shares of Collegium Pharmaceutical from $45.00 to $48.00 and gave the stock a “buy” rating in a research note on Friday, November 7th. Wall Street Zen upgraded shares of Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. Weiss Ratings upgraded shares of Collegium Pharmaceutical from a “hold (c+)” rating to a “buy (b-)” rating in a report on Monday. Finally, HC Wainwright increased their price objective on shares of Collegium Pharmaceutical from $44.00 to $46.00 and gave the stock a “buy” rating in a research report on Friday, November 7th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Buy” and an average price target of $47.00.

Collegium Pharmaceutical Stock Performance

Shares of COLL opened at $48.86 on Monday. The company has a current ratio of 1.36, a quick ratio of 1.27 and a debt-to-equity ratio of 2.71. The firm’s fifty day simple moving average is $40.14 and its two-hundred day simple moving average is $35.71. Collegium Pharmaceutical has a 12 month low of $23.23 and a 12 month high of $49.09. The stock has a market capitalization of $1.54 billion, a P/E ratio of 30.35 and a beta of 0.61.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings data on Wednesday, September 4th. The specialty pharmaceutical company reported $1.26 earnings per share (EPS) for the quarter. Collegium Pharmaceutical had a return on equity of 102.03% and a net margin of 7.72%.The company had revenue of $135.55 million for the quarter. As a group, analysts predict that Collegium Pharmaceutical will post 5.62 EPS for the current year.

Insider Activity

In other Collegium Pharmaceutical news, CFO Colleen Tupper sold 30,000 shares of Collegium Pharmaceutical stock in a transaction dated Thursday, November 6th. The stock was sold at an average price of $40.53, for a total transaction of $1,215,900.00. Following the completion of the transaction, the chief financial officer owned 126,667 shares in the company, valued at approximately $5,133,813.51. The trade was a 19.15% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Rita J. Balice-Gordon sold 3,650 shares of the business’s stock in a transaction that occurred on Friday, December 5th. The stock was sold at an average price of $47.03, for a total value of $171,659.50. Following the sale, the director directly owned 52,629 shares of the company’s stock, valued at $2,475,141.87. This represents a 6.49% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 51,250 shares of company stock worth $2,235,352 over the last three months. 2.51% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Connor Clark & Lunn Investment Management Ltd. bought a new stake in Collegium Pharmaceutical during the first quarter worth $3,085,000. Nuveen LLC purchased a new position in Collegium Pharmaceutical during the 1st quarter worth $2,674,000. Public Sector Pension Investment Board grew its stake in shares of Collegium Pharmaceutical by 26.7% in the 1st quarter. Public Sector Pension Investment Board now owns 102,246 shares of the specialty pharmaceutical company’s stock worth $3,052,000 after acquiring an additional 21,562 shares in the last quarter. Tejara Capital Ltd raised its holdings in shares of Collegium Pharmaceutical by 288.4% in the first quarter. Tejara Capital Ltd now owns 111,792 shares of the specialty pharmaceutical company’s stock valued at $3,337,000 after purchasing an additional 83,011 shares during the last quarter. Finally, Brandywine Global Investment Management LLC raised its holdings in shares of Collegium Pharmaceutical by 13.7% in the first quarter. Brandywine Global Investment Management LLC now owns 114,763 shares of the specialty pharmaceutical company’s stock valued at $3,426,000 after purchasing an additional 13,792 shares during the last quarter.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.